About the Event
Each year 500,000 women in the United States opt for a tubal ligation to prevent future pregnancies. This expensive procedure is currently the only available method of permanent female contraception and requires hospitalization, surgery, anesthesia, and a long recovery time.
AltaScience, a Dublin-based medical technology company, has developed a permanent, removable intra-tubal contraceptive device that is painlessly implanted in a gynecologist’s office without anesthesia in a matter of minutes. Based on the Celt Arterial Closure Device which has been proven in over 90,000 patients, AltaSeal IV Micro-Insert has been in development since 2013 and undergone proof of concept testing in 84 women over the past 5 years with no pregnancies or serious adverse events.
Based on this success, AltaScience is now moving towards an IDE submission with the FDA in preparation for clinical trials.
Join our webinar to hear from AltaScience CEO, David O’Flynn, as he talks about the significant breakthrough the AltaSeal IV Micro-Insert represents in reproductive health, and the opportunity it offers for millions of women looking for an alternative to tubal ligation.